VIVES is a multi-sector fund that invests in projects with a positive societal impact
Founded at the end of the nineties, NeuroTECH was co-founded by Mr. Troosters and three members of UCLouvain (Prof. C. Trullemans, Prof. Cl. Veraart and Dr. J. Delbeke).
During the first years and in...
IntoPIX is an independent and innovative technology provider with world-class expertise and knowledge in video processing and compression, cryptography, high performance computing and microelectronics...
Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models.
With the...
Vincent Mouret, Chairman of the Board of Cissoid:
"As Chairman of the board of Cissoid, I’ve been working closely to VIVES for the last 10 years. I have really appreciated VIVES involvement and...
Gael Rouvroy, CEO intoPIX:
"VIVES fund has been a great partner in early and mature stages of intoPIX. They recognized the potential of the market and the technology with a primary recognition for...
Pierre Blondeau, CEO Upstreem:
"We have been working since 2017 with VIVES II, which has joined us since the beginning of our adventure. VIVES II team has an in-depth understanding of all aspects of...
Proceeds will advance clinical development of Nuclidium’s true theranostic pipeline and expand its global production and manufacturing network for copper-based radiopharmaceuticals
Participation is
NVD003 is a bone grafting material developed to surgically treat patients with Congenital Pseudarthrosis of the Tibia, a rare and difficult-to-treat pediatric disease
Four young patients were treated
VIVES Partners’ portfolio investment The Akkermansia Company (TAC) acquired by Danone
Acquisition of TAC’s gut microbiota product, with benefits for people at risk of cardiovascular disease